Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShort-Term Debt repayments
Ratios

Arrowhead Pharmaceuticals (ARWR) Depreciation & Amortization (IS) (2016 - 2017)

Arrowhead Pharmaceuticals (ARWR) has disclosed Depreciation & Amortization (IS) for 7 consecutive years, with $1.1 million as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Depreciation & Amortization (IS) fell 3.75% year-over-year to $1.1 million, compared with a TTM value of $4.6 million through Dec 2017, up 27.24%, and an annual FY2017 reading of $4.7 million, up 43.88% over the prior year.
  • Depreciation & Amortization (IS) was $1.1 million for Q4 2017 at Arrowhead Pharmaceuticals, down from $1.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization (IS) topped out at $8.8 million in Q2 2013 and bottomed at $270417.0 in Q3 2014.
  • Average Depreciation & Amortization (IS) over 5 years is $1.1 million, with a median of $799130.5 recorded in 2015.
  • The sharpest move saw Depreciation & Amortization (IS) surged 1969.31% in 2013, then crashed 96.85% in 2014.
  • Year by year, Depreciation & Amortization (IS) stood at $403405.0 in 2013, then dropped by 28.1% to $290039.0 in 2014, then surged by 173.88% to $794349.0 in 2015, then soared by 49.26% to $1.2 million in 2016, then decreased by 3.75% to $1.1 million in 2017.
  • Business Quant data shows Depreciation & Amortization (IS) for ARWR at $1.1 million in Q4 2017, $1.2 million in Q3 2017, and $1.2 million in Q2 2017.